TELA Bio

139 articles about TELA Bio

• TELA Bio to Announce Third Quarter 2022 Financial Results

  10/27/2022

  TELA Bio, Inc. announced that the company will report third quarter 2022 financial results on Wednesday, November 9th, 2022.

• TELA Bio Announces Publication of 24-Month BRAVO Study Results Demonstrating Benefits of OviTex® Reinforced Tissue Matrix in Hernia Repair

  10/26/2022

  TELA Bio, Inc., a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy, announced the publication of the 24-month analysis from the BRAVO Study in Annals of Medicine and Surgery.

• TELA Bio to Participate in Inaugural Gilmartin Group Emerging Growth Company Showcase

  8/23/2022

  TELA Bio, Inc. ("TELA"), today announced that the Company will participate in the Gilmartin Group Emerging Growth Company Showcase on August 31st, 2022.

• TELA Bio Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriter’s Option to Purchase Additional Shares

  8/18/2022

  TELA Bio, Inc. announced the closing of its previously announced underwritten public offering of 4,600,000 shares of its common stock at a price to the public of $8.00 per share, including 600,000 shares sold pursuant to the full exercise of the underwriter’s option to purchase additional shares, for gross proceeds of $36.8 million, before deducting underwriting discounts and commissions and other estimated offering expenses.

• TELA Bio Announces Pricing of Public Offering of Common Stock - Aug 16, 2022

  8/16/2022

  TELA Bio, Inc. announced the pricing of its previously announced underwritten public offering of 4,000,000 shares of its common stock at a price to the public of $8.00 per share, for gross proceeds of $32.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses.

• TELA Bio Announces Proposed Public Offering of Common Stock - Aug 15, 2022

  8/15/2022

  TELA Bio, Inc. announced that it has commenced an underwritten public offering of shares of its common stock.

• TELA Bio Reports Second Quarter 2022 Financial Results

  8/10/2022

  TELA Bio, Inc., a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, reported financial results for the second quarter ended June 30, 2022.

• TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 29, 2022

  7/29/2022

  TELA Bio, Inc. announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of stock options to purchase an aggregate of 58,075 shares of its common stock to 25 newly-hired employees, with a grant date of July 26, 2022.

• TELA Bio Awarded Synthetic Bioabsorbable Mesh Products Agreement with Premier, Inc.

  7/20/2022

  TELA Bio, Inc. today announced that it has been awarded a group purchasing agreement for Synthetic Bioabsorbable Mesh Products with Premier, Inc.

• TELA Bio to Participate in Upcoming JMP Securities Life Sciences Conference - June 02, 2022

  6/2/2022

  TELA Bio, Inc. announced that the Company will participate in the JMP Securities Life Sciences Conference on June 16th, 2022.

• TELA Bio Secures Up to $50 Million in Debt Financing from MidCap Financial

  5/31/2022

  TELA Bio, Inc. today announced that the Company has entered into a new credit facility with MidCap Financial (“MidCap”), providing TELA with access to up to $50 million in total credit.

• TELA Bio to Participate in Upcoming Jefferies Healthcare Conference

  5/26/2022

  TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy, today announced that the Company will participate in the Jefferies Healthcare Conference on June 8th , 2022.

• TELA Bio Reports First Quarter 2022 Financial Results

  5/10/2022

  TELA Bio, Inc. reported financial results for the first quarter ended March 31, 2022.

• TELA Bio to Participate in Upcoming 2022 H.C. Wainwright Annual Global Investment Conference

  5/9/2022

  TELA Bio, Inc. announced that the Company will participate in the 2022 H.C. Wainwright Annual Global Investment Conference on May 24th, 2022.

• TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Apr 29, 2022

  4/29/2022

  TELA Bio, Inc. announced that the Compensation Committee of the Board of Directors of TELA approved inducement grants of stock options to purchase an aggregate of 50,950 shares of its common stock to 13 newly-hired employees, with a grant date of April 27, 2022.

• TELA Bio to Announce First Quarter 2022 Financial Results

  4/26/2022

  TELA Bio, Inc. announced that the company will report first quarter 2022 financial results on Tuesday, May 10, 2022.

• TELA Bio Appoints D. Taylor Ocasio as General Counsel

  4/18/2022

  TELA Bio, Inc., a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, announced the hiring of D. Taylor Ocasio as the Company's new General Counsel.

• TELA Bio to Participate in Upcoming Needham & Co. 21st Annual Healthcare Virtual Conference

  3/30/2022

  TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy, today announced that the Company will participate in the Needham & Co. 21st Annual Healthcare Virtual Conference on April 12th, 2022.

• TELA Bio Reports Fourth Quarter and Full Year 2021 Financial Results

  3/21/2022

  TELA Bio, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2021.

• TELA Bio to Participate in Upcoming Canaccord Genuity Musculoskeletal Conference in Chicago, IL

  3/16/2022

  TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy, today announced that the Company will participate in the Canaccord Geunity Musculoskeletal Conference on March 22, 2022 in Chicago, IL.